4 quarters tracked · Beat rate 50% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $5.39 | $6.63 | +23.1% | Beat |
| Q4 2025 | 2025-12-31 | $5.96 | $6.04 | +1.4% | Beat |
| Q3 2025 | 2025-09-30 | $4.84 | $4.50 | -7.0% | Miss |
| Q2 2025 | 2025-06-30 | $6.03 | $5.96 | -1.1% | Miss |
Earnings Beat Rate
Novo Nordisk A/S has beaten analyst EPS estimates in 2 of 4 tracked quarters (50% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →